Analyst Reco. Kura Oncology, Inc.

Equities

KURA

US50127T1097

Real-time Estimate Cboe BZX Other stock markets 01:46:20 2024-05-24 pm EDT			5-day change	1st Jan Change
21.44 ^USD	+0.02%		-2.55%	+50.24%

May. 15	Transcript : Kura Oncology, Inc. Presents at Bank of America Health Care Conference 2024, May-15-2024 10:40 AM
May. 14	Kura Oncology Enrolls 85 Patients in Ziftomenib Trial for Leukemia Drug	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Mizuho Securities Initiates Kura Oncology With Buy Rating, Price Target is $26	Dec. 22	MT
Wedbush Lowers Kura Oncology's PT to $37 From $40, Adjusts Valuation, Market Assumptions After Q3 Results; Keeps Outperform Rating	Nov. 03	MT
Kura Oncology Says Tipifarnib Shows Overall Response Rate of 30%, 20% in Assessments for Squamous Cell Carcinoma	23-10-17	MT
BofA Securities Initiates Coverage on Kura Oncology with Buy Rating, $31 Price Target	23-08-11	MT
Scotiabank Starts Kura Oncology at Sector Perform With $10.50 Price Target	23-07-27	MT
Stifel Adjusts Price Target on Kura Oncology to $25 From $24, Maintains Buy Rating	23-06-12	MT
BTIG Initiates Kura Oncology at Buy With $31 Price Target	23-05-17	MT
Stifel Starts Kura Oncology at Buy With $25 Price Target	23-01-31	MT
Credit Suisse Raises Kura Oncology's PT to $29 from $27 to Reflect Changes to Market Model, Point of Sale for Ziftomenib; Maintains Outperform Rating	22-07-13	MT
Cantor Fitzgerald Initiates Coverage on Kura Oncology With Overweight Rating, $30 Price Target	22-07-12	MT
SVB Leerink Lowers Kura Oncology's Price Target to $28 From $41, Maintains Outperform Rating	22-02-25	MT
Credit Suisse Lifts Kura Oncology's Price Target to $27 from $25, Notes Rich Catalyst Lineup Into H2; Keeps Outperform Rating	22-02-25	MT
Jefferies Financial Initiates Kura Oncology at Buy, Sets Price Target at $35	22-02-15	MT
Credit Suisse Lifts Kura Oncology's Price Target to $25 from $21, Maintains Outperform Rating	22-02-14	MT
Kura Oncology Reports 56% Overall Response Rate in T-Cell Lymphoma Drug Study	21-12-13	MT
Credit Suisse Adjusts Kura Oncology's Price Target to $21 From $40, Keeps Outperform Rating	21-11-26	MT
HC Wainwright Adjusts Price Target on Kura Oncology to $32 From $43, Maintains Buy Rating	21-11-24	MT
Wedbush Cuts Kura Oncology's Price Target to $40 From $53 After KO-539 Partial Clinical Hold; Outperform Rating Kept	21-11-24	MT
KURA ONCOLOGY : Credit Suisse Lowers Kura Oncology's PT to $40 from $42, Updates Model with Q2 Actuals, Adjusts KO-539 Launch Trajectory Assumptions; Keeps Outperform Rating	21-08-06	MT
KURA ONCOLOGY : SVB Leerink Adjusts Price Target on Kura Oncology to $40 From $42, Maintains Outperform Rating	21-02-26	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Kura Oncology, Inc.

Equities

KURA

US50127T1097

Analyst Reco.

Filters